Medtronic Refutes Claims Of Gaps In Infuse Adverse-Event Reporting
This article was originally published in Clinica
Executive Summary
Medtronic has lashed back at a media news report claiming the medical device giant did not properly report adverse events during a 206-2008 chart review of its Infuse biologic-based spinal bone growth product.
You may also be interested in...
Medtronic Expects Settlements Of Infuse Suits
The company said in a US SEC filing that it’s reached agreements to settle almost 6,000 outstanding patient injury suits tied to the spine device. Terms of the settlements weren't disclosed.
Court Revives Medtronic Stock Fraud Case
Three pension plans sued the company on the grounds that it hid risks posed by the off-label use of the Infuse bone cement product. The case was dismissed by a lower court last fall as having been filed outside the statute of limitations, but the Eighth Circuit Court of Appeals ruled the claims to be valid.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.